BusinessFrance

Bioamber produces bio-based 1,4-butanediol on industrial scale

28.03.2012 - Bioamber Inc. is one step closer to the environmental summit. The company's goal is to establish sustainable, "green" chemistry on an industrial scale.

The French/US enterprise has now scaled up its hydrogenation catalyst technology for converting biologically produced succinic acid into 1,4-butanediol (1,4-BDO), tetrahydrofuran (THF) and gamma-butyrolactone (GBL). These bulk chemicals are needed for making polyesters, polyurethanes, spandex and biodegradable plastics. The global addressable market for these products exceeds $4bn, according to BioAmber, with an annual market for 1,4-BDO alone of 1.3m tons. Bio-succinate has being produced since 2010 near Reims in a huge 350,000L fermenter from corn. Other production sites are planned for Canada (Sarnia, Ontario) and Thailand. According to Chief Technology Officer Jim Millis, Bioamber "is developing an integrated plant engineering design that combines the production of bio-succinic acid and bio-based 1,4-BDO on a single site". So far bio-succinate comes from Bioamber S.A.S's factory in France (Banzancourt/Pomacle). The endeavour to refine succinate into 1,4-BDO was undertaken together with DuPont (USA) which is one of the world's leading commercial catalyst suppliers. After successfully having established industrial C4-chemistry based on renewable resources, Bioamber is in the process of producing a C6-molecule (adipic acid), also in a sustainable manner. However, industrial production is not anticipated to start before 2015.

http://www.european-biotechnology-news.com/news/business/2012-01/bioamber-produces-bio-based-14-butanediol-on-industrial-scale.html

AntibodiesDenmarkNetherlands

22.05.2015 Dutch arGEN-X and Danish LEO Pharma are pairing up to develop antibody-based treatments for the chronic inflammation that causes many skin conditions.

M&ANetherlandsGermanyEU

12.05.2015 US pharma is coming to European biotech to fill their pipeline. Pfizer is paying €77.5m for an option on Dutch AM-Pharma, while Juno Therapeutics acquired German biotech Stage Cell Therapeutics for around €72m.

Rare diseasesItalyGermanyPoland

15.05.2015 Rome-based pharmaceutical group Sigma-Tau has sold its blood cancer drug programme Oncaspar to US company Baxter, who aims to spin out its biopharma business.



BiologicsFinlandNetherlandsEU

26.05.2015 The Finnish Medicines Agency Fimea has joined the Dutch MEB in its stance on the interchangeability of biosimilars. The Fimea now sees physician-driven switching of biologics as unproblematic.

SurveyGermany

06.05.2015 More revenue, more staff, more funding: in the German biotech industry, all signs are pointing towards growth.

M&AUKSweden

18.05.2015 Double deal for allergy: UK’s speciality biopharma Circassia is boosting its asthma pipeline with the acquisition of Swedish asthma specialist Aerocrine as well as fellow British Prosonix.

BusinessSwedenFrance

02.06.2015 After disappointing Phase III results for immunotherapy tasquinimod and the subsequent discontinuation of the prostrate cancer drug, Swedish Active Biotech is now severely downsizing its operations.

FinancingUK

20.05.2015 The Scottish Government has announced it will double the amount of funds for rare diseases. The New Medicines Fund that was created last year for this purpose will be increased to £80m (€112m).

EPOSwitzerland

30.05.2015 Pharma giant Roche has out-licensed its anaemia drug Mircera to fellow Swiss healthcare company Galenica.

Events

All Events

Partner-Events

Frankfurt am Main (DE)

ACHEMA 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CHRONTECH PHARMA (S)0.02 SEK100.00%
  • NEOVACS (F)1.25 EUR15.74%
  • SCANCELL HOLDINGS (UK)38.25 GBP14.18%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)22.00 SEK-53.97%
  • ANTISOMA (UK)1.00 GBP-35.48%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%

TOP

  • CHRONTECH PHARMA (S)0.02 SEK100.0%
  • HYBRIGENICS (F)1.86 EUR44.2%
  • GALAPAGOS (B)51.13 EUR36.1%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)22.00 SEK-56.7%
  • CYTOS (CH)0.61 CHF-39.6%
  • ANTISOMA (UK)1.00 GBP-35.5%

TOP

  • CELLECTIS (F)38.35 EUR517.6%
  • WILEX (D)4.30 EUR465.8%
  • ADOCIA (F)69.01 EUR432.9%

FLOP

  • CHRONTECH PHARMA (S)0.02 SEK-81.8%
  • THROMBOGENICS (B)5.32 EUR-70.2%
  • ACTIVE BIOTECH (S)10.60 SEK-68.8%

No liability assumed, Date: 01.06.2015